Waldenström macroglobulinaemia: the key questions
- 8 May 2013
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 162 (3), 295-303
- https://doi.org/10.1111/bjh.12367
Abstract
No abstract availableThis publication has 70 references indexed in Scilit:
- Hematopoietic cell transplantation for Waldenström macroglobulinemiaBone Marrow Transplantation, 2011
- High response rate and durable remissions following fludarabine and rituximab combination therapy for chronic cold agglutinin diseaseBlood, 2010
- Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) GuidelinesMayo Clinic Proceedings, 2010
- Bortezomib in Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2009
- Prognostic Relevance of 6q Deletion in Waldenström's Macroglobulinemia: A Multicenter StudyClinical Lymphoma Myeloma and Leukemia, 2009
- Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group–directed intergroup trial S9003Blood, 2009
- The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)Leukemia, 2008
- Rituximab for the treatment of autoimmune cytopenias.Haematologica, 2007
- Systemic AL amyloidosis due to non‐Hodgkin's lymphoma: an unusual clinicopathologic associationBritish Journal of Haematology, 2004
- Treatment of Waldenstrom Macroglobulinemia with 2-ChlorodeoxyadenosineAnnals of Internal Medicine, 1993